GlassScriptPhysician profile
William H Bachman
NPI 1245851039
$1,519.07
in general payments reported to CMS, 2019-2025
20 companies · $995 in 2025
The $995 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $71.37 · 2024: $453 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $435.16 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $261.55 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $135.23 | 2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $130.01 | 2024-2025 | |
| Glaxosmithkline, LLC. | $117.36 | 2024-2025 | Trelegy Ellipta |
| Abbvie INC. | $51.57 | 2023-2024 | Vraylar |
| Exact Sciences Corporation | $49.63 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.19 | 2025 | Jardiance |
| Corcept Therapeutics | $44.63 | 2025 | Korlym |
| Abbott Laboratories | $40.17 | 2025 | Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $24.62 | 2025 | Thinprep 2000 Processor, Aptima |
| Olympus America INC. | $23.74 | 2025 | Itind System |
| Dynavax Technologies Corporation | $23.61 | 2023-2024 | Heplisav-B |
| Avadel Cns Pharmaceuticals, LLC | $23.05 | 2025 | Lumryz |
| Ultragenyx Pharmaceutical INC. | $22.00 | 2024 | Crysvita |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $21.38 | 2025 | Rexulti |
| Amgen INC. | $18.14 | 2024 | Evenity, Prolia |
| Actelion Pharmaceuticals US, INC. | $17.30 | 2025 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $17.03 | 2025 | |
| Rgh Enterprises LLC | $13.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bachman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.